Bionova Scientific LLC, an Asahi Kasei company and a bespoke contract development and manufacturing organization (CDMO), announced a strategic manufacturing alliance with Syenex, a genetic medicines ...
An update from the phase 2 LEGEND trial shows that the investigational nonviral gene therapy detalimogene voraplasmid has achieved a 62% complete response rate at six months in patients with high-risk ...
Asimov’s LV Edge Packaging cell line routinely achieves high titers for therapeutic transgenes and is now available at AGC Biologics’ Cell and Gene Center of ExcellenceBOSTON & MILAN--(BUSINESS WIRE)- ...
A patient death in a CRISPR trial halts gene editing studies, raising critical safety questions. What this means for the ...
Plasmid DNA purification techniques have evolved significantly in response to the growing demand for high‐quality nucleic acids in gene therapy and vaccine production. Classical methods, including ...
HOPEWELL, N.J., June 27, 2025 /PRNewswire/ -- ProBio, a global contract development and manufacturing organization (CDMO) specializing in cell and gene therapy, today announced the opening of its ...
U.S. Pharmacopeia (USP), the independent organization that helps develop quality standards for pharmaceuticals, has launched new standards for viral vectors that they hope will help the rapidly ...
The Asia-Pacific gene therapy market was valued at $349.1 million in 2020 and is expected to grow at a compound annual growth rate (CAGR) of 36.8% to reach nearly $7 billion in 2030. This predicted ...
Elenagen™, a novel DNA plasmid therapy that previously demonstrated high clinical benefit and low toxicity in cancer patients, has now shown significant promise in alleviating chronic pain ...
A new gene-editing technique enables the correction of multiple genetic mutations simultaneously, transforming the prospects for millions living with complex inherited diseases, such as cystic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback